Shots:

• Synaffix is eligible to receive $246M upfront & milestones along with royalties on net sales. ProfoundBio to get non-exclusive license rights to use Synaffix’s ADC technologies for one therapeutic program to targets specific TAA & also retains license option rights to a second TAA
• The agreement will access Synaffix’s linker-payload technologies including GlycoConnect & HydraSpace to optimize ADCs therapeutic properties
• ProfoundBio will be responsible for the research- development- manufacturing & commercialization of ADC products. Synaffix will support ProfoundBio’s research activities & responsible for the manufacturing of components specifically related to its ADC’s technologies

  | Ref: Businesswire | Image: Synaffix